Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.82 +12.0%	$1.59	$1.33 ▼ $3.58	$85.74M	0.6	56,495 shs	78,965 shs
ARCT Arcturus Therapeutics	$12.20 -4.7%	$11.37	$8.04 ▼ $45.00	$330.88M	2.36	450,391 shs	353,268 shs
CDTX Cidara Therapeutics	$24.28 -5.5%	$20.72	$10.14 ▼ $28.42	$304.64M	0.86	78,223 shs	163,459 shs
CYRX Cryoport	$6.04 -2.9%	$5.93	$4.58 ▼ $11.64	$302.83M	1.92	543,684 shs	253,099 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-2.11%	-8.19%	+12.07%	-22.58%	-37.74%
ARCT Arcturus Therapeutics	+5.35%	+9.97%	+5.18%	-27.97%	-60.47%
CDTX Cidara Therapeutics	-2.10%	+22.15%	+16.92%	+19.70%	+108.27%
CYRX Cryoport	+1.30%	-7.58%	+11.87%	0.00%	-46.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.0803 of 5 stars	3.3	5.0	0.0	1.0	1.7	0.0
ARCT Arcturus Therapeutics	2.9906 of 5 stars	4.6	0.0	0.0	3.3	2.5	0.6
CDTX Cidara Therapeutics	4.3897 of 5 stars	4.6	4.0	4.6	2.1	0.8	0.0
CYRX Cryoport	3.0436 of 5 stars	4.4	1.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.50	Moderate Buy	$8.00	339.56% Upside
ARCT Arcturus Therapeutics	3.13	Buy	$57.80	373.77% Upside
CDTX Cidara Therapeutics	3.22	Buy	$41.86	72.39% Upside
CYRX Cryoport	2.71	Moderate Buy	$11.00	82.12% Upside

Current Analyst Ratings Breakdown

Latest ADAG, CDTX, CYRX, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00
5/9/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $47.00
5/8/2025	CYRX Cryoport	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
5/5/2025	CYRX Cryoport	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $7.00
4/29/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$46.00 ➝ $46.00

(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$103.20K	830.78	N/A	N/A	$1.61 per share	1.13
ARCT Arcturus Therapeutics	$131.27M	2.52	N/A	N/A	$10.42 per share	1.17
CDTX Cidara Therapeutics	$302K	1,008.75	N/A	N/A	($1.82) per share	-13.34
CYRX Cryoport	$232.13M	1.30	$0.36 per share	16.95	$9.45 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$18.95M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/11/2025 (Estimated)
CYRX Cryoport	-$99.59M	-$2.34	N/A	N/A	N/A	-70.08%	-13.35%	-6.43%	8/5/2025 (Estimated)

Latest ADAG, CDTX, CYRX, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/7/2025	Q1 2025	CYRX Cryoport	-$0.23	-$0.22	+$0.01	-$0.28	$56.19 million	$41.04 million
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A
3/4/2025	Q4 2024	CYRX Cryoport	-$0.33	-$0.42	-$0.09	-$0.42	$58.71 million	$59.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	5.86%	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX Cryoport	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.08	2.50	N/A
ARCT Arcturus Therapeutics	N/A	4.76	4.76
CDTX Cidara Therapeutics	N/A	3.54	3.54
CYRX Cryoport	0.48	5.70	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
ARCT Arcturus Therapeutics	94.54%
CDTX Cidara Therapeutics	35.82%
CYRX Cryoport	92.90%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
ARCT Arcturus Therapeutics	16.60%
CDTX Cidara Therapeutics	3.89%
CYRX Cryoport	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	34.89 million	Not Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
CYRX Cryoport	1,020	50.14 million	44.44 million	Optionable

ADAG, CDTX, CYRX, and ARCT Headlines

Recent News About These Companies

Point72 Asset Management L.P. Has $2.74 Million Stock Position in Cryoport, Inc. (NASDAQ:CYRX)

May 23 at 4:36 AM | marketbeat.com

Silvercrest Asset Management Group LLC Buys 323,216 Shares of Cryoport, Inc. (NASDAQ:CYRX)

May 21 at 5:42 AM | marketbeat.com

Millennium Management LLC Purchases 409,353 Shares of Cryoport, Inc. (NASDAQ:CYRX)

May 21 at 4:54 AM | marketbeat.com

D. E. Shaw & Co. Inc. Grows Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

May 21 at 4:03 AM | marketbeat.com

Jacobs Levy Equity Management Inc. Invests $572,000 in Cryoport, Inc. (NASDAQ:CYRX)

May 20 at 4:38 AM | marketbeat.com

Cryoport, Inc. (NASDAQ:CYRX) Shares Sold by Cubist Systematic Strategies LLC

May 17, 2025 | marketbeat.com

Analysts Offer Insights on Industrial Goods Companies: CryoPort (CYRX), Regal Rexnord (RRX) and Transdigm Group (TDG)

May 14, 2025 | theglobeandmail.com

Cryoport, Inc. (NASDAQ:CYRX) Shares Sold by Algert Global LLC

May 13, 2025 | marketbeat.com

Dimensional Fund Advisors LP Buys 63,301 Shares of Cryoport, Inc. (NASDAQ:CYRX)

May 13, 2025 | marketbeat.com

Q2 Earnings Forecast for Cryoport Issued By Leerink Partnrs

May 13, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for Cryoport Q2 Earnings

May 13, 2025 | marketbeat.com

Roth Capital Forecasts Cryoport's Q2 Earnings (NASDAQ:CYRX)

May 13, 2025 | americanbankingnews.com

Cryoport, Inc.: Cryoport Reports First Quarter 2025 Financial Results

May 12, 2025 | finanznachrichten.de

Does CryoPort (CYRX) Have the Potential to Rally 54.74% as Wall Street Analysts Expect?

May 12, 2025 | zacks.com

Fred Alger Management LLC Decreases Position in Cryoport, Inc. (NASDAQ:CYRX)

May 11, 2025 | marketbeat.com

Cryoport's (CYRX) "Buy" Rating Reaffirmed at Needham & Company LLC

May 10, 2025 | marketbeat.com

Cryoport, Inc. (CYRX) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Earnings Roundup: Cumberland Pharmaceuticals, Cryoport, Harrow Health

May 9, 2025 | nashvillepost.com

Cryoport, Inc. (NASDAQ:CYRX) Q1 2025 Earnings Call Transcript

May 9, 2025 | msn.com

Tudor Investment Corp ET AL Purchases 116,803 Shares of Cryoport, Inc. (NASDAQ:CYRX)

May 8, 2025 | marketbeat.com

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, CDTX, CYRX, and ARCT Company Descriptions

Adagene NASDAQ:ADAG

$1.82 +0.20 (+12.00%)

Closing price 03:59 PM Eastern

Extended Trading

$1.83 +0.01 (+0.55%)

As of 04:32 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Arcturus Therapeutics NASDAQ:ARCT

$12.20 -0.60 (-4.69%)

Closing price 04:00 PM Eastern

Extended Trading

$12.26 +0.06 (+0.46%)

As of 04:37 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Cidara Therapeutics NASDAQ:CDTX

$24.28 -1.42 (-5.53%)

Closing price 04:00 PM Eastern

Extended Trading

$24.35 +0.07 (+0.29%)

As of 05:43 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cryoport NASDAQ:CYRX

$6.04 -0.18 (-2.89%)

Closing price 04:00 PM Eastern

Extended Trading

$6.04 0.00 (0.00%)

As of 04:04 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time